Shares of Novo Nordisk edged up 1.8% to $39.10 Tuesday after the Danish drugmaker reported that women in a late-stage trial of its next-generation obesity injection lost an average of 25% of their body weight over 68 weeks — new evidence that CagriSema can improve upon the weight loss delivered by its blockbuster Wegovy. The bump is modest for a stock that has shed roughly 30% over the past year, and investors must decide whether this data point marks the start of a comeback or a footnote in an ongoing slide.
• Women Lost More Than the Overall Trial Group, and That Matters Commercially. In the full trial of more than 3,400 adults, CagriSema had led to 22.7% weight loss — below the 25% Novo had targeted. The new women-specific analysis hit that 25% mark, with results ranging from 26.7% in premenopausal women to 23.1% in postmenopausal women. Since women made up about 67% of participants in the study, stronger results in this group give Novo a marketing narrative aimed at the largest segment of the obesity-drug customer base — particularly women navigating menopause-related weight gain.
• The Fine Print: This Is Backward-Looking Analysis, Not a New Trial. A post hoc subgroup analysis carries materially less evidentiary weight than the pre-specified topline, both for regulators and for the market.
The results are based on an ideal scenario in which all patients stayed on treatment without interruptions — a best-case assumption that inflates the headline number. Novo itself described the analyses as "hypothesis-generating and requiring further study."
• Sales Forecasts Have Already Been Slashed — Recovery Depends on FDA Timing. Before CagriSema's disappointing topline results in early 2026, analysts estimated peak sales could be $20 billion. After the miss, Barclays cut its peak sales estimate to $2 billion from $12 billion, calling the news a "worst-case scenario." However, CagriSema recently received FDA approval, positioning Novo with peak annual sales estimates ranging from $18 billion to $24 billion across the analyst community. That wide range reflects genuine uncertainty. The company expects an FDA decision within the last three months of 2026, and pricing near the $1,400–$1,600/month range will determine whether it can compete with Eli Lilly's rival treatments.
• The Stock Is Cheap — But Cheap for a Reason. NVO trades at roughly a P/E of about 8.6 times earnings, with a market cap near $171 billion — a fraction of its mid-2024 peak. The stock is down 29% over the past 12 months and 24% year-to-date. Today's data doesn't change the fundamental question: can CagriSema's launch close the gap with Lilly, or merely slow the bleeding?